DIAGNOSTIC SOLUTIONS & HEALTHCARE CHALLENGES

AST / MIC / Resistance Testing

The global incidence of multi-drug resistance (MDR) among gram-negative and gram-positive pathogens has risen in recent years, with serious consequences for both hospital- and community-acquired infections.

Faits marquants

AST / MIC / Resistance Testing

Detecting the potential resistance mechanisms of organisms with high mortality rates such as Enterococcus fae­cium, Staphylococcus aureus, Klebsiella pneu­moniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp. and Escherichia coli is of high clinical and epidemiological importance.

MALDI-TOF mass spectrometry has the potential to identify specific resistance markers. When using the IVD MALDI Biotyper® the dedicated MBT Subtyping® IVD Module combines the identification of important pathogens with automated subsequent detection of specific resistance markers in one automated workflow, providing a warning about a potential resistance.

With the subsequent MBT-STAR® IVD assays, the IVD MALDI Biotyper® combines microbial identification with phenotypic detection of carbapenemase and cephalosporinase activity.

The MICRONAUT broth microdilution (BMD) product portfolio provides accurate, complete and true MIC of microorganisms as well as detection of important resistance mechanisms of Ambler class A (ESBL, KPC), class B (MBL), class C (AMP-C) and class D (OXA-48-like) cephalosporinases and / or carbapenemases.

Bruker further supports resistance management by offering a real-time PCR kit to detect presence of the big 5 carbapenemase genes from a rectal swab, for patients who are at risk of colonization from Carbapenamase Producing Enterobacteriaceae (CPE).